Category IP-Watch Briefs

US Chamber Of Commerce Releases 2011 IP Policy Agenda

The United States Chamber of Commerce, the industry lobbying giant in Washington, has issued its 2011 intellectual property agenda. The list of suggested legislative changes to be made by the Obama administration and the US Congress aim at further increasing resources and support for IP enforcement, including legislation to block websites deemed to infringe on IP rights.

Leaks Show Real Aim Of ACTA, As Trade Chief Declares It Binding

The recently completed Anti-Counterfeiting Trade Agreement (ACTA), negotiated by the countries that own most of the world's intellectual property rights, is aimed at developing countries they hope will give value to those rights by protecting them, leaked documents show, according to French group La Quadrature du Net.

US IP Enforcement Coordinator Issues Annual Report

The United States Intellectual Property Enforcement Coordinator today issued an annual report on IP enforcement. One year after her appointment, Coordinator Victoria Espinel claimed significant progress on the plan for the office set up to coordinate IP enforcement activities across various US government agencies.

Financial Crisis Increased ICT Exports From Asia

The United Nations Conference on Trade and Development (UNCTAD) released data today that show Asian economies increased their share of global exports of information and communication technology (ICT) goods in 2009 over the previous year. This means the global financial crisis further shifted trade in these goods toward Asia, UNCTAD said.

US Legislation Would Prevent Patents On Tax Strategies

A bill was introduced into the United States Senate last week that would prevent any individual or company from being able to get a patent on a tax strategy. The bill also is included in the patent reform bill reintroduced into the Senate Judiciary Committee last week and expected to come up as soon as this week.

GSK Critiques Anti-Counterfeiting Trade Agreement

Pharmaceutical giant GlaxoSmithKline has taken a stance on the Anti-Counterfeiting Trade Agreement (ACTA), welcoming most of its provisions, but requesting a harmonised approach for implementation, because the much-debated agreement would leave a lot of space for differing national implementations. GSK…